##### 



Exhibit
10.2
 RESEARCH, DEVELOPMENT
AND COMMERCIALIZATION AGREEMENT
 Agreement  th
  Roche Nutley Roche Basel Roche
  Miikana
 *
 *
 * *
 * *
 * * *
   
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission.




---



##### 



ARTICLE 1
 DEFINITIONS
  Affiliate
 Combination Product
 Commencement
 Commercialize
 Compound *  * *
 Controlled
 Derivative * *
 Development Plan
 Dollars $
 Effective Date
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -2-




---



##### 



FDA
 FD&C Act
 Field
 First Commercial Sale
 Global Alliance Director
 IND
 Inventions
 Know How
 Licensed Product
 Maior Market *
 Miikana Group
 Miikana Know-How
 Miikana Patent Rights
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -3-




---



##### 



NDA
 Net Sales provided
  Patent
 Phase I
 Phase II
 
 *
    
    The marked portions have been omitted pursuant to a request
for confidential treatment and filed separately with the Securities Exchange Commission. -4-




---



##### 



Phase III
 Registration
 Regulatory Agency
 Regulatory, Filing
 Roche Know-How
 Roche Patent Rights
 Territory
 Third Party
 Transfer Know-How
 US
 Valid Claim
 
 *
    
    The marked portions have been omitted pursuant to a request
for confidential treatment and filed separately with the Securities Exchange Commission. -5-




---



##### 



*
 ARTICLE 2
 GRANT OF LICENSE
 Grant *
 Right to Sublicense
 Covenant Regarding License Scope
 Diligence * * *
 
 *
    
    The marked portions have been omitted pursuant to a request
for confidential treatment and filed separately with the Securities Exchange Commission. -6-




---



##### 



ARTICLE 3
 RESEARCH AND DEVELOPMENT REIMBURSEMENT AND MILESTONE
PAYMENTS
 Fees * *
 Time
    
    AmountBy the earlier of either (a) June 30, 2005, or (b) the closing date
of Miikanas Series B Financing
    
    *By September 30, 2005
    
    *
 * * * *
 Milestone Payments *
 Milestones
    
    Payments (Dollars)Commencement Phase III
    
    *NDA Filing in the USA
    
    *NDA Filing outside the USA
    
    *First Commercial Sale in the USA
    
    *First Commercial Sale outside the USA
    
    *First time annual sales in the Territory exceed *
    
    *First time annual sales in the Territory exceed *
    
    *
  
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -7-




---



##### 



ARTICLE 4
 ROYALTIES
 Royalties in General *  *
 Total, Territory wide Annual Net Sales in a single calendar year
    
    Royalty RateAmount of Net Sales up to and including *
    
    *Amount of Net Sales over * and up to and including *
    
    *Amount of Net Sales over * and up to and including *
    
    *Amount of Net Sales over *
    
    *
 Accrual of Royalties
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -8-




---



##### 



Reduction for Third Party Licenses
 *
 *
 * *
 ARTICLE 5
 ROYALTY REPORTS AND ACCOUNTING
 Royalty Payments; Royalty Reports Royalty Report
      *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential treatment
and filed separately with the Securities Exchange Commission. -9-




---



##### 



Exchange Rate; Manner of Payment *
 Payment Due Dates *
  Account of.
    
    Hoffmann-La Roche IncAccount No.:
    
    *Bank Name:
    
    **ABA Routing No:
    
    *
 Right to Audit
 * * *
 *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -10-




---



##### 



*
  * * * *
 Confidentiality of Records
 Recruiting of forecasted sales * * *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -11-




---



##### 



ARTICLE
6
 RESEARCH, DEVELOPMENT AND MARKETING
 Development
 Liaison
  *
 *
 *
 *
 *
  Development Program
 Development
Program  * *
  
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -12-




---



##### 



*
  * *
 ARTICLE
7
 PATENT RIGHTS
 Patent Prosecution and Maintenance
   
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -13-




---



##### 



Discontinuance/Abandonment Abandoning Party * *
 Status of Patent Rights *
 Ownership of Future Inventions and Know-How
  Miikana
Inventions
 Roche
Inventions
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -14-




---



##### 



ARTICLE
8
 INFRINGEMENT
 Applicability
 Third Party Infringement
 Field Infringement Notifying Party *
   
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -15-




---



##### 



* * * *
    * *
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -16-




---



##### 



* * *
  provided however
 ARTICLE
9
 REPRESENTATIONS AND WARRANTIES
 Representations and Warranties of Roche
      
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -17-




---



##### 



* * *
 Representations and Warranties of Miikana
       
 *
    
    The marked portions have been omitted pursuant to a request for confidential treatment
and filed separately with the Securities Exchange Commission. -18-




---



##### 



Disclaimer of Warranties
 ARTICLE
10
 CONFIDENTIALITY
 Treatment of Confidential Information *
 Right to Disclose
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential treatment
and filed separately with the Securities Exchange Commission. -19-




---



##### 



Release From Restrictions
     Confidentiality of Agreement
 Return of Confidential Information
 ARTICLE
11
 TRANSFERS AND ACCESS-REGULATORY
 Transfer of Know-How *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential treatment
and filed separately with the Securities Exchange Commission. -20-




---



##### 



*
 Support * * * * * *
 Regulatory Affairs
   Meetings with Regulatory Authorities
 Supply of Active Compound * * * *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential treatment
and filed separately with the Securities Exchange Commission. -21-




---



##### 



* * * * * * * * * * * -
 Product Recalls
 ARTICLE
12
 TERM AND TERMINATION
 Term
 Miikana Right to Terminate
 For Material Breach at any Time * *
 For Convenience * *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential treatment
and filed separately with the Securities Exchange Commission. -22-




---



##### 



EU Termination * *
 Roches Right to Terminate
 For Material Breach at any Time * *
 For Miikanas Discontinuance of the Development Plan
 General Effect of Expiration or Termination
 Rights Upon Expiration or Any Termination
  
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -23-




---



##### 



Rights Upon Certain Miikana Terminations
 *
  Rights Upon Roche Termination for Cause and Other Miikana Terminations
 Reverted Territory: Reverted Products
 No Further Representations
 Technology License
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -24-




---



##### 



Remaining Quantities * *
 No Further Sales *
 Cross-Border Sales After Partial Termination
 ARTICLE
13
 INDEMNIFICATION
 Indemnification by Miikana
  
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -25-




---



##### 



Indemnification by Roche
    Indemnification Procedures With Respect to Third Party Claims
  
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -26-




---



##### 



ARTICLE
14
 GENERAL PROVISIONS
 Force Maieure =
 Further Assurances
 Severabilitv
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -27-




---



##### 



Notices *
  
 
  
 
  
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. 
 -28-




---



##### 



Assignment
 Performance by Affiliates
 Publicity
 Amendment
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -29-




---



##### 



Entire Agreement
 Waiver
 No Implied Licenses
 No Joint Venture
 No Third Party Beneficiaries
 Limitation of Liability
 Governing Law
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -30-




---



##### 



Headings
 Counterparts
 Dispute Resolution
   Hoffmann-La Roche Inc.By:
    
    /s/ Hoffmann La-Roche Inc.Name:Title:F. Hoffmann-La Roche Ltd F.
    
    Hoffmann-La Roche LtdBy:
    
    /s/ F. Hoffmann-La Roche Ltd.
    
    
    
    By:
    
    /s/ F. Hoffmann-La Roche LtdName:
    
    
    
    
    
    Name:Title:
    
    
    
    
    
    Title:Miikana Therapeutics Inc.By:
    
    /s/ Dinesh V. PatelName: Dinesh V. Patel, Ph.D.Title: President
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -31-




---



##### 



Appendix A
 List of Roche Patent Rights
 
 Count Code
    
    Application No.
    
    Patent No.*
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *




---



##### 



Count Code
    
    Application No.
    
    Patent No.*
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -2-




---



##### 



Appendix A
 List of Roche Patent Rights (continued)
 Roche Patent Series 20077
 Count Code
    
    Application No.
    
    Patent No.*
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request
for confidential treatment and filed separately with the
Securities Exchange Commission. -3-




---



##### 



Count Code
    
    Application No.
    
    Patent No.*
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. -4-




---



##### 



Count Code
    
    Application No.
    
    Patent No.*
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a
request for confidential treatment and filed separately
with the Securities Exchange Commission. -5-




---



##### 



Appendix A
 List of Roche Patent Rights (continued)
 
 Country Code
    
    Application No.
    
    Patent No.*
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
    
    **
    
    *
    
    **
    
    **
    
    *
    
    **
    
    **
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -6-




---



##### 



Country Code
    
    Application No.
    
    Patent No.*
    
    *
    
    **
    
    **
    
    *
    
    **
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    **
    
    *
    
    **
    
    *
    
    **
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    **
    
    **
    
    **
    
    *
    
    **
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -7-




---



##### 



Country Code
    
    Application No.
    
    Patent No.*
    
    *
    
    **
    
    *
    
    **
    
    **
    
    **
    
    **
    
    *
    
    **
    
    **
    
    *
    
    **
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -8-




---



##### 



Appendix A
 List of Roche Patent Rights (continued)
 Roche Patent Series 20524
 Country Code
    
    Application No.
    
    Patent No.*
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
    
    **
    
    *
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -9-




---



##### 



Country Code
    
    Application No.
    
    Patent No.*
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
    
    **
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -10-




---



##### 



Appendix A
 List of Roche Patent Rights (continued)
 Roche Patent Series 20690
 Country Code
    
    Application No.
    
    Patent No.*
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -11-




---



##### 



Appendix A
 List of Roche Patent Rights (continued)
 Roche Patent Series 20798
 Country Code
    
    Application No.
    
    Patent No.*
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
    
    **
    
    **
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -12-




---



##### 



Appendix A
 List of Roche Patent Rights (continued)
 Roche Patent Series 20865
 Country Code
    
    Application No.
    
    Patent No.*
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. -13-




---



##### 



APPENDIX B
 Transfer of Know How
 
 Binder No./Color
    
    Description
    
    Date
    
    HLR No.*
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
    
    **
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *




---



##### 



Binder No./Color
    
    Description
    
    Date
    
    HLR No.*
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    **
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    **
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
 Green Corner ReportNo./Binder No.
    
    Description**
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential treatment
and filed separately with the Securities Exchange Commission. 2




---



##### 



*
    
    **
    
    ***
    
    ************
    
    **
    
    **
    
    ****************
    
    ****
    
    ****
 Binder No./Color
    
    Description*
    
    **
    
    **
 Binder No./Color
    
    Description*
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for
confidential treatment and filed separately with the Securities Exchange Commission. 3




---



##### 



*
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *1**
 Binder No./Color
    
    Description**************
 
 1  
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission. 4




---



##### 



Appendix C
 Development Plan
 Phase 2:
 Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *
 *
    
    
    *
    
    
    *
    
    
    *
    
    
    **
    
    
    *
    
    
    *
    
    
    *
    
    
    *




---



##### 



*Phase 1b/ co-administration \trialsØ
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission.




---



##### 



Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *Ø
    
    *
 *
    
    
    *
    
    
    *
    
    
    *
    
    
    **
    
    
    *
    
    
    *
    
    
    *
    
    
    *
 *o
    
    *o
    
    *o
    
    *o
    
    *o
    
    *o
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission.




---



##### 



*o
    
    
    
    *o
    
    
    
    *o
    
    
    
    **o
    
    *o
    
    *o
    
    *o
    
    *o
    
    *§
    
    *§
    
    *§
    
    *§
    
    *§
    
    *o
    
    *o
    
    *o
    
    *o
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission.




---



##### 



*
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
 
 *
    
    The marked portions have been omitted pursuant to a request for confidential
treatment and filed separately with the Securities Exchange Commission.




---



##### 



Appendix D
 Active Compound Specifications




---



##### 



Appendix E
 Stock Purchase Agreement